Millennium Management LLC Purchases 288,259 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Millennium Management LLC increased its holdings in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 188.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 440,944 shares of the company's stock after purchasing an additional 288,259 shares during the quarter. Millennium Management LLC owned 0.86% of Cardiff Oncology worth $1,914,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in Cardiff Oncology by 68.7% during the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock worth $1,253,000 after purchasing an additional 117,514 shares in the last quarter. Laurion Capital Management LP bought a new stake in Cardiff Oncology during the 4th quarter worth approximately $2,504,000. American Century Companies Inc. grew its stake in shares of Cardiff Oncology by 12.8% during the 4th quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock worth $234,000 after acquiring an additional 6,140 shares in the last quarter. Northern Trust Corp grew its stake in shares of Cardiff Oncology by 8.9% during the 4th quarter. Northern Trust Corp now owns 337,092 shares of the company's stock worth $1,463,000 after acquiring an additional 27,489 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Cardiff Oncology by 24.0% during the 4th quarter. Rhumbline Advisers now owns 53,172 shares of the company's stock worth $231,000 after acquiring an additional 10,290 shares in the last quarter. 16.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their price target on shares of Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, May 9th.

Cardiff Oncology Price Performance

Shares of CRDF traded up $0.11 during mid-day trading on Wednesday, hitting $3.62. 1,605,662 shares of the company's stock were exchanged, compared to its average volume of 1,149,623. The company has a market cap of $240.82 million, a PE ratio of -3.85 and a beta of 1.61. Cardiff Oncology, Inc. has a 52 week low of $2.01 and a 52 week high of $5.64. The company has a 50-day simple moving average of $2.86 and a 200 day simple moving average of $3.45.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.09 million. Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. On average, analysts anticipate that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current year.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.